Robert P. Anderson
www.immusant.com
0000-0002-0764-7267
ImmusanT Inc
2 papers found
Refreshing results…
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Circulating gluten‐specific, but not CMV‐specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire
Missing publications? Search for publications with a matching author name.